Smallpox cost-effectiveness of therapy: Difference between revisions
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
| Line 7: | Line 7: | ||
==Cost-Effectiveness of Therapy== | ==Cost-Effectiveness of Therapy== | ||
Since there is no available [[antiviral]] treatment for [[smallpox]], the [[vaccine]] is the only potential cost.<ref name="MooreSeward2006">{{cite journal|last1=Moore|first1=Zack S|last2=Seward|first2=Jane F|last3=Lane|first3=J Michael|title=Smallpox|journal=The Lancet|volume=367|issue=9508|year=2006|pages=425–435|issn=01406736|doi=10.1016/S0140-6736(06)68143-9}}</ref> | |||
In the past the development and distribution of the bifurcated [[needle]] represented one of the costs. This [[needle]] improved the ease and cost of [[vaccination]] | In the past, the development and distribution of the bifurcated [[needle]] represented one of the costs. This [[needle]] improved the ease and diminished the cost of [[vaccination]]. About 1,000 needles cost about $5. The [[needle]] could be boiled and reused multiple times. Also, since these [[needle]] required a smaller amount of [[vaccine]], the vials of this could now vaccinate 4 times as many people. This was an important achievement since there were certain countries that could not afford any sort of [[vaccination]] above a very minimal cost. | ||
==References== | ==References== | ||
Revision as of 19:09, 11 July 2014
|
Smallpox Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Smallpox cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Smallpox cost-effectiveness of therapy |
|
Risk calculators and risk factors for Smallpox cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
The efforts made in the eradication smallpox were cost-effective since the disease was successfully eradicated in 1980.
Cost-Effectiveness of Therapy
Since there is no available antiviral treatment for smallpox, the vaccine is the only potential cost.[1]
In the past, the development and distribution of the bifurcated needle represented one of the costs. This needle improved the ease and diminished the cost of vaccination. About 1,000 needles cost about $5. The needle could be boiled and reused multiple times. Also, since these needle required a smaller amount of vaccine, the vials of this could now vaccinate 4 times as many people. This was an important achievement since there were certain countries that could not afford any sort of vaccination above a very minimal cost.
References
- ↑ Moore, Zack S; Seward, Jane F; Lane, J Michael (2006). "Smallpox". The Lancet. 367 (9508): 425–435. doi:10.1016/S0140-6736(06)68143-9. ISSN 0140-6736.